PDLIM7 and neoplasm: Early phase clinical trial of intratumoral administration of EBV-LMP1 targeted DNAzyme in conjunction with radiotherapy reported a significant reduction in short-term tumour regression with minimal adverse events associated with the combined treatment (Cao et al., 2014; Liao et al., 2014).